HC Wainwright & Co. Maintains Buy on WAVE Life Sciences, Lowers Price Target to $13

Benzinga Newsdesk www.benzinga.com Negative 50.5%

Neg 50.5% Neu 0% Pos 0%

HC Wainwright & Co. analyst Andrew S. Fein maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy and lowers the price target from $18 to $13.